Samsung Biologics Strikes $400m+ Biosimilars Supply Deal With Pfizer

‘Long Term’ Arrangement Covers ‘Large-Scale Manufacturing’ For Pfizer Portfolio

 
• By Dave Wallace

Samsung Biologics has struck a deal worth over $400m to manufacture multiple biosimilars for Pfizer.

Manufacturing production line of vials
Samsung Biologics will manufacture biosimilars for Pfizer • Source: Shutterstock

More from Deals

More from Business